140 related articles for article (PubMed ID: 9720544)
1. Compliance of clinical stage I nonseminomatous germ cell tumor patients with surveillance.
Hao D; Seidel J; Brant R; Alexander F; Ernst DS; Summers N; Russell JA; Stewart DA
J Urol; 1998 Sep; 160(3 Pt 1):768-71. PubMed ID: 9720544
[TBL] [Abstract][Full Text] [Related]
2. Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres.
Ernst DS; Brasher P; Venner PM; Czaykowski P; Moore MJ; Reyno L; Winquist E; Segal R; Hao D
Can J Urol; 2005 Apr; 12(2):2575-80. PubMed ID: 15877938
[TBL] [Abstract][Full Text] [Related]
3. A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year followup.
Nicolai N; Pizzocaro G
J Urol; 1995 Sep; 154(3):1045-9. PubMed ID: 7637051
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment.
Ondrus D; Matoska J; Belan V; Kausitz J; Goncalves F; Hornák M
Eur Urol; 1998; 33(6):562-6. PubMed ID: 9743698
[TBL] [Abstract][Full Text] [Related]
5. Clinical stage I testis cancer: long-term outcome of patients on surveillance.
Sogani PC; Perrotti M; Herr HW; Fair WR; Thaler HT; Bosl G
J Urol; 1998 Mar; 159(3):855-8. PubMed ID: 9474168
[TBL] [Abstract][Full Text] [Related]
6. Surveillance can be the standard of care for stage I nonseminomatous testicular tumors and even high risk patients.
Roeleveld TA; Horenblas S; Meinhardt W; van de Vijver M; Kooi M; ten Bokkel Huinink WW
J Urol; 2001 Dec; 166(6):2166-70. PubMed ID: 11696728
[TBL] [Abstract][Full Text] [Related]
7. The value of prognostic factors in the management of stage I nonseminomatous germ cell testicular tumors (NSGCTT).
Ondrus D; Goncalves F; Kausitz J; Mat'oska J; Belan V
Neoplasma; 1996; 43(3):195-7. PubMed ID: 8841507
[TBL] [Abstract][Full Text] [Related]
8. Difficulties of a surveillance study omitting retroperitoneal lymphadenectomy in clinical stage I nonseminomatous germ cell tumors of the testis.
Pizzocaro G; Zanoni F; Salvioni R; Milani A; Piva L; Pilotti S
J Urol; 1987 Dec; 138(6):1393-6. PubMed ID: 2824862
[TBL] [Abstract][Full Text] [Related]
9. Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis.
Amato RJ; Ro JY; Ayala AG; Swanson DA
Urology; 2004 Jan; 63(1):144-8; discussion 148-9. PubMed ID: 14751368
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors-is shift to risk adapted policy justified?
Divrik RT; Akdoğan B; Ozen H; Zorlu F
J Urol; 2006 Oct; 176(4 Pt 1):1424-29; discussion 1429-30. PubMed ID: 16952649
[TBL] [Abstract][Full Text] [Related]
11. Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer.
Böhlen D; Burkhard FC; Mills R; Sonntag RW; Studer UE
J Urol; 2001 Feb; 165(2):441-4. PubMed ID: 11176393
[TBL] [Abstract][Full Text] [Related]
12. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group.
Huddart RA; O'Doherty MJ; Padhani A; Rustin GJ; Mead GM; Joffe JK; Vasey P; Harland SJ; Logue J; Daugaard G; Hain SF; Kirk SJ; MacKewn JE; Stenning SP;
J Clin Oncol; 2007 Jul; 25(21):3090-5. PubMed ID: 17634488
[TBL] [Abstract][Full Text] [Related]
13. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.
Böhlen D; Borner M; Sonntag RW; Fey MF; Studer UE
J Urol; 1999 Apr; 161(4):1148-52. PubMed ID: 10081858
[TBL] [Abstract][Full Text] [Related]
14. [Use of prognostic factors of disease progression in the treatment of patients with stage I nonseminomatous testicular tumors].
Ondrus D
Bratisl Lek Listy; 1999 Jan; 100(1):61-5. PubMed ID: 10493000
[TBL] [Abstract][Full Text] [Related]
15. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience.
Gels ME; Hoekstra HJ; Sleijfer DT; Marrink J; de Bruijn HW; Molenaar WM; Freling NJ; Droste JH; Schraffordt Koops H
J Clin Oncol; 1995 May; 13(5):1188-94. PubMed ID: 7537802
[TBL] [Abstract][Full Text] [Related]
16. Active surveillance after orchiectomy for nonseminomatous testicular germ cell tumors: late relapse may occur.
Boyer MJ; Cox K; Tattersall MH; Findlay MP; Grygiel J; Rogers J
Urology; 1997 Oct; 50(4):588-92. PubMed ID: 9338737
[TBL] [Abstract][Full Text] [Related]
17. Orchiectomy alone for clinical stage I nonseminomatous germ cell tumors of the testis (NSGCTT): a minimum follow-up period of 5 years.
Ondrus D; Hornak M
Tumori; 1994 Oct; 80(5):362-4. PubMed ID: 7839467
[TBL] [Abstract][Full Text] [Related]
18. Clinical stage I nonseminomatous germ cell tumors of the testis in childhood and adolescence: an analysis of 31 cases.
Terenziani M; Piva L; Spreafico F; Salvioni R; Massimino M; Luksch R; Cefalo G; Casanova M; Ferrari A; Polastri D; Mazza E; Bellani FF; Nicolai N
J Pediatr Hematol Oncol; 2002; 24(6):454-8. PubMed ID: 12218592
[TBL] [Abstract][Full Text] [Related]
19. Unilateral laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular neoplasm.
Bianchi G; Beltrami P; Giusti G; Tallarigo C; Mobilio G
Eur Urol; 1998; 33(2):190-4. PubMed ID: 9519363
[TBL] [Abstract][Full Text] [Related]
20. Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors.
Spermon JR; Roeleveld TA; van der Poel HG; Hulsbergen-van de Kaa CA; Ten Bokkel Huinink WW; van de Vijver M; Witjes JA; Horenblas S
Urology; 2002 Jun; 59(6):923-9. PubMed ID: 12031382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
